LTR Pharma drug ROXUS begins US prescription fulfillment
Shares of LTR Pharma (LTP.AX) rose as much as 13.3% to A$0.560 after the company said its erectile dysfunction treatment ROXUS began prescription fulfillment in the US via online platform Mavrox. The stock is down 28.3% year-to-date.
560, their highest level since August 11, after the company said first patient prescriptions have now been filled for ROXUS in the US. The biopharmaceutical company said the nasal spray treatment for erectile dysfunction can now be obtained through Mavrox, an online men's health platform. LTR Pharma said it will focus on supporting US partners as prescribing and prescription activity builds. 3% year to date.